Exelixis, Inc. (EXEL) fair value analysis
Nasdaq · Updated 2026-10-19
EXEL price how computed
Forward Fair Value verdict
Fairly valuedEXEL is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $62.23
- Sector
- Healthcare
- 12-month range
- $37.90–$62.83
- Market cap
- $15.4B
- From 52-week high
- -1.0%
- Shares outstanding
- 248M
- Rank in Healthcare by discount to fair value
- #48 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Exelixis, Inc. is a biopharmaceutical company that develops and commercializes oncology medicines, focusing on treatments for various types of cancer. The company operates in the United States and internationally, conducting research, development, and sales activities across multiple markets.
EXEL currently ranks #48 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $15.4B
- P/E (trailing)
- 18x
- Revenue (TTM)
- $2.44B
- Net margin
- 35.3%
- EPS (TTM)
- $3.41
- Gross margin
- 96.7%
- Debt / equity
- 0.09
- Revenue growth (3-yr avg)
- 11.1%
- Shares outstanding
- 248M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 66 · neutral
- 50-day average
- $56.79
- 200-day average
- $49.85
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+9.3%)
2026-03 ▲ beat (+14.5%)
2025-12 ▲ beat (+16.0%)
2025-09 ▲ beat (+16.4%)
2025-06 ▲ beat (+15.4%)
2025-03 ▲ beat (+69.1%)
2024-12 ▲ beat (+12.2%)
2024-09 ▲ beat (+11.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 10 hold · 1 sell (18 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $54.9
- Target vs last price
- -11.8%
What our data shows for EXEL
- Our model validated 17 trailing price-to-earnings windows for EXEL, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $37.90–$62.83.
- The 14-day relative strength index sits at a neutral 66.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for EXEL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent EXEL news
TickrTrends' derived news-sentiment signal for EXEL is currently leaning positive, computed from recent coverage.
- EXEL Maintained by Citizens -- Price Target Raised to $65.00 (gurufocus.com, 2026-10-19)
TickrTrends take: Citizens maintained its rating on EXEL while raising the price target to $65, which provides a data point for assessing whether the stock's current market price aligns with analyst expectations in the Healthcare sector. Given TickrTrends' fairly valued assessment, this price target adjustment may indicate how the market is pricing in recent developments relative to fundamental value. Valuation-focused readers should monitor whether the stock trades toward or away from this $65 target, as such movement could signal shifts in how the market perceives EXEL's worth relative to its peers in Healthcare. - Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering (manilatimes.net, 2026-10-13)
TickrTrends take: Akari Therapeutics has appointed an experienced executive to lead business development efforts, signaling management's focus on partnerships and strategic growth initiatives. For a company trading at a fairly valued level within the competitive Healthcare sector, the success of new partnership deals and licensing arrangements will be key metrics to monitor, as these could materially impact future revenue streams and valuation multiples. Investors following TickrTrends' assessment should watch for announcements regarding collaborations or development agreements that could shift the company's growth trajectory and justify any potential revaluation. - Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? (insidermonkey.com, 2026-09-17)
TickrTrends take: Exelixis is experiencing a regulatory delay with its zanzalintinib candidate, which introduces uncertainty into its near-term pipeline catalysts during a period when TickrTrends considers the stock undervalued. The extended review timeline means investors should monitor whether the additional three months yields data sufficiently compelling to support approval, as the resolution of this review will be material to validating the current valuation thesis in the Healthcare sector. Valuation-focused readers should track both the regulatory decision timeline and any interim data disclosures that could clarify the probability of a successful outcome.
More EXEL news
- Exelixis Inc at Morgan Stanley Global Healthcare Conference Transcript (gurufocus.com, 2026-09-15)
What people are saying
Follow the EXEL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — EXEL's valuation status shifted from undervalued to fairly valued this week, reflecting changes in TickrTrends' derived indicators within the healthcare sector. This adjustment suggests that recent market movements or updated financial metrics have realigned the company's pricing with its estimated intrinsic value.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — EXEL's valuation assessment shifted this week as the DCF cross-check band moved from undervalued to fairly valued, indicating a narrowing of the margin between the stock's price and its intrinsic value estimate. Despite this change in the DCF indicator, EXEL maintains an overall undervalued verdict from TickrTrends' derived indicators. The Healthcare sector company's valuation positioning reflects the reassessment captured in this week's update.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is EXEL stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), EXEL is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is EXEL's TickrTrends verdict?
EXEL's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does EXEL compare to other Healthcare stocks?
EXEL ranks #48 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is EXEL overbought or oversold?
EXEL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does EXEL report earnings next?
EXEL's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does EXEL usually beat earnings estimates?
Over its last 8 reported quarters EXEL beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about EXEL?
Of 18 analysts covering EXEL, 7 rate it a buy, 10 a hold and 1 a sell - hold-leaning, with a consensus price target of $54.9 (-11.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
EXEL vs ENSG · EXEL vs HCSG · EXEL vs HSIC · EXEL vs INVA · EXEL vs IQV